As cutaneous squamous cell carcinoma (CSCC) progresses, so does its complexity—
and its threat

Take a
deeper
look

CSCC is a commonly occurring
type of cancer.
Annual US incidence of
CSCC is estimated to be1-4:


700,000a
and rising
a As of 2012. Read about the rising
incidence of CSCC

While early-stage CSCC generally has a good prognosis, certain tumor and patient factors can indicate a greater risk for recurrence or metastasis.5-9

More than
80%
of disease-specific death was reported to be caused by locoregional disease that has not distantly metastasized (M0).10,11

Download this patient fact sheet for information about advanced CSCC to share with your patients.

References: 1. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081-1086. 2. Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease [published online June 29, 2016]. Am J Clin Dermatol. 2016;17(5):491-508. doi:10.1007/s40257-016-0207-3. 3. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957-966. 4. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069-1080. 5. Skin cancer treatment (PDQ®). National Cancer Institute website. https://www.cancer.gov/types/skin/hp/skin-treatment-pdq. Updated February 1, 2018. Accessed February 13, 2018. 6. Referenced with permission from NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Squamous Cell Skin Cancer V.2.2018. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed March 8, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. 7. Jennings L, Schmults CD. Management of high-risk cutaneous squamous cell carcinoma. J Clin Aesthet Dermatol. 2010;3(4):39-48. 8. Stratigos A, Garbe C, Lebbe C, et al, on behalf of European Dermatology Forum, European Association of Dermato-Oncology, and European Organization for Research and Treatment of Cancer. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(14):1989-2007. 9. Califano JA, Lydiatt WM, Nehal KS, et al. Cutaneous squamous cell carcinoma of the head and neck. In: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017:171-181. 10. Motaparthi K, Kapil JP, Velazquez EF. Cutaneous squamous cell carcinoma: review of the eighth edition of the American Joint Committee on Cancer staging guidelines, prognostic factors, and histopathologic variants. Adv Anat Pathol. 2017;24(4):171-194. 11. Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013;149(5):541-547.